Encision Inc ECIA
We take great care to ensure that the data presented and summarized in this overview for ENCISION INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ECIA
Top Purchases
Top Sells
About ECIA
Encision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.
Insider Transactions at ECIA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 23
2024
|
Peter D Geary Dir of Strategic Integation |
BUY
Sale (or disposition) back to the issuer
|
Direct |
3,500
+5.49%
|
$0
$0.5 P/Share
|
|
Dec 23
2024
|
Peter D Geary Dir of Strategic Integation |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+7.27%
|
$0
$0.35 P/Share
|
|
Dec 23
2024
|
Gregory J. Trudel CEO |
BUY
Sale (or disposition) back to the issuer
|
Direct |
3,500
+1.16%
|
$0
$0.5 P/Share
|
|
Dec 23
2024
|
Gregory J. Trudel CEO |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+1.62%
|
$0
$0.35 P/Share
|
|
Dec 23
2024
|
Brian J Jackman VP Marketing |
BUY
Sale (or disposition) back to the issuer
|
Direct |
3,500
+15.81%
|
$0
$0.5 P/Share
|
|
Dec 23
2024
|
Brian J Jackman VP Marketing |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+18.42%
|
$0
$0.35 P/Share
|
|
Aug 29
2024
|
Robert H Fries Director |
BUY
Open market or private purchase
|
Direct |
35,000
+5.6%
|
$0
$0.37 P/Share
|
|
Aug 20
2024
|
Gregory J. Trudel CEO |
BUY
Open market or private purchase
|
Direct |
3,300
+1.1%
|
$0
$0.32 P/Share
|
|
Apr 12
2024
|
Patrick W Pace Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,286
+50.0%
|
$0
$0.34 P/Share
|
|
Apr 01
2024
|
Mala M Ray VP Finance |
BUY
Sale (or disposition) back to the issuer
|
Direct |
13,435
+38.75%
|
$0
$0.75 P/Share
|
|
Apr 01
2024
|
Mala M Ray VP Finance |
BUY
Grant, award, or other acquisition
|
Direct |
19,667
+36.2%
|
$0
$0.44 P/Share
|
|
Mar 29
2024
|
Peter D Geary Dir of Strategic Integation |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+31.11%
|
$0
$0.38 P/Share
|
|
Mar 29
2024
|
Gregory J. Trudel CEO |
BUY
Sale (or disposition) back to the issuer
|
Direct |
125,627
+42.65%
|
$0
$0.75 P/Share
|
|
Mar 29
2024
|
Peter D Geary Dir of Strategic Integation |
BUY
Sale (or disposition) back to the issuer
|
Direct |
11,259
+37.53%
|
$0
$0.75 P/Share
|
|
Mar 28
2024
|
Peter D Geary Dir of Strategic Integation |
BUY
Sale (or disposition) back to the issuer
|
Direct |
11,259
+16.08%
|
$0
$0.75 P/Share
|
|
Mar 28
2024
|
Gregory J. Trudel CEO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+40.44%
|
$0
$0.34 P/Share
|
|
Mar 05
2024
|
Brian J Jackman VP Marketing |
BUY
Sale (or disposition) back to the issuer
|
Direct |
34,030
+41.69%
|
$0
$0.46 P/Share
|
|
Mar 05
2024
|
Brian J Jackman VP Marketing |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+33.59%
|
$0
$0.36 P/Share
|
|
Nov 18
2022
|
Robert H Fries Director |
BUY
Open market or private purchase
|
Direct |
6,069
+1.04%
|
$0
$0.46 P/Share
|
|
Nov 16
2022
|
Robert H Fries Director |
BUY
Open market or private purchase
|
Direct |
18,931
+3.19%
|
$0
$0.44 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 15K shares |
|---|---|
| Sale (or disposition) back to the issuer | 10.5K shares |
| Open market or private purchase | 38.3K shares |
| Exercise of conversion of derivative security | 10.3K shares |